Skip to main content
SpringerLink
Log in

Sipuleucel-T

APC 8015, APC-8015, Prostate Cancer Vaccine — Dendreon

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Dendreon Corporation. Dendreon Grants Kirin HLA-DR Antibody License to Regain Asian Rights to Provenge Immunotherapy. Media Release: 14 Nov 2003. Available from URL: http://www.dendreon.com

    Google Scholar 

  2. Dendreon Corporation. FDA Agrees to Special Protocol Assessment Amendment to D9902B ‘IMPACT’ Study of PROVENGE. Media Release: 29 Nov 2005. Available from URL: http://www.dendreon.com

    Google Scholar 

  3. Dendreon Corporation. Dendreon’s Second Randomized Phase 3 D9902A Trial Shows Provenge Extends Survival in Patients With Advanced Prostate Cancer. Media Release: 21 Jul 2005. Available from URL: http://www.dendreon.com

    Google Scholar 

  4. Dendreon Corporation. Dendreon D9901 Phase 3 Data Showing Provenge Significantly Improves Survival in Advanced Prostate Cancer Patients Presented at ASCO. Media Release: 14 May 2005. Available from URL: http://www.dendreon.com

    Google Scholar 

  5. Dendreon Corporation. Dendreon Announces Provenge Significantly Improves Survival in Men With Advanced Prostate Cancer. Media Release: 17 Feb 2005. Available from URL: http://www.dendreon.com

    Google Scholar 

  6. Dendreon Corporation. Dendreon Announces Results of D9905 Phase 2 Study of Provenge in Patients with Early Stage Prostate Cancer. Media Release: 24 May 2005. Available from: URL: http://www.dendreon.com

    Google Scholar 

  7. Dendreon Corporation. Dendreon Corporation Receives FDA Fast Track Designation for Provenge. Media Release: 4 Sep 2003. Available from URL: http://www.dendreon.com

    Google Scholar 

  8. Dendreon Corporation. Dendreon Announces FDA Grants Fast Track Status for PROVENGE. Media Release: 7 Nov 2005. Available from URL: http://www.dendreon.com

    Google Scholar 

  9. Dendreon Corporation. Dendreon Reports Combination of Provenge and Avastin Impacts PSA Doubling Time In Patients With Biochemically-Relapsed Prostate Cancer. Media Release: 19 Feb 2005. Available from URL: http://www.dendreon.com

    Google Scholar 

  10. Dendreon Corporation. Dendreon Reports Preliminary D9902A Trial Data For Provenge in Patients With Advanced Prostate Cancer. Media Release: 11 Jan 2005. Available from URL: http://www.dendreon.com

    Google Scholar 

  11. Small EJ, Rini B, Higano C, et al. A randomized, placebo-ontrolled phase III trial of APC8015 in patients with androgen-independent prostate cancer. 39th Annual Meeting of the American Society of Clinical Oncology: 382 (plus oral presentation) abstr. 1534, 31 May 2003

    Google Scholar 

  12. Dendreon Corporation. Dendreon Announces Preliminary Analysis of its First Phase III Provenge Trial; Results Support New Approach in Fighting Prostate Cancer. Media Release: 9 Aug 2002._Available from URL: http://www.dendreon.com

    Google Scholar 

  13. Dendreon Corporation. Dendritic cell immunotherapy for prostate cancer stimulates immune response, delays disease progression. Media Release [1 page], 16 May 1999. Available from URL: http://www.dendreon.com

    Google Scholar 

  14. Burch PA, Breen JK, Buckner JC, et al. Priming tissue-pecific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clinical Cancer Research 6: 2175–2182, Jun 2000

    PubMed  CAS  Google Scholar 

  15. Valone F, Small E, Peshwa MV, et al. Phase I trial of dendritic cell-based immunotherapy with APC8015 for hormone-refractory prostate cancer. 89th Annual Meeting of the American Association for Cancer Research: 173, 28 Mar 1998

    Google Scholar 

  16. Dendreon Corporation. Results of Phase 2 Combination Therapy Trial of Provenge and Bevacizumab. Media Release: 2 Jun 2003._Available from URL: http://www.dendreon.com

    Google Scholar 

  17. Rini BI, Weinberg V, Bok RA, et al. A phase 2 study of prostatic acid phosphatase-pulsed dendritic cells (APC8015; provenge) in combination with bevacizumab in patients with serologic progression of prostate cancer after local therapy. 39th Annual Meeting of the American Society of Clinical Oncology: 174, 31 May 2003

    Google Scholar 

  18. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. Journal of Clinical Oncology 18: 3894–3903, 1 Dec 2000

    PubMed  CAS  Google Scholar 

  19. Fong L, Benike C, Brockstedt C, et al. Immunization with dendritic cells pulsed with xenogeneic prostatic acid phosphatase administered via different routes induces cellular immune responses in prostate cancer patients. 90th Annual Meeting of the American Association for Cancer Research: 85–86, 10 Apr 1999

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sipuleucel-T. Drugs R D 7, 197–201 (2006). https://doi.org/10.2165/00126839-200607030-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200607030-00006

Keywords

Search

Navigation